Cross-tolerance studies in the spinal cord of β-FNA-treated mice provides further evidence for delta opioid receptor subtypes

Mehmet Sofuoglu, P. S. Portoghese, A. E. Takemori

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Abstract

In this study we investigated the development of cross-tolerance among intrathecally (i.t.)- administered mu and delta opioid receptor selective peptides in β-funaltrexamine (β-FNA)-treated mice. Tolerance to the antinociceptive effect of i.t. administered DPDPE was accomplished by administration of 16 nmol/mouse of DPDPE, i.t. 3 hr before testing in β-FNA-treated mice (10 μmol/kg, s.c., 24 hr before the experiment). Cross-tolerance developed to the antinociceptive effect of i.t. administered DADLE but not to those of DSLETT or DAMGO. DSLET (0.1 nmol/mouse i.t.) administration in β-FNA-treated mice resulted in tolerance development to its antinociceptive effect. The same pretreatment resulted in a marginally significant increase in the antinociceptive ED50 value of DPDPE. There was no cross-tolerance to the antinociceptive effect of i.t. administered DADLE or DAMGO. These results provide further evidence for the existence of delta opioid receptor subtypes where DADLE and DPDPE interact with one site and DSLET with a different one.

Original languageEnglish (US)
Pages (from-to)PL153-PL156
JournalLife Sciences
Volume49
Issue number19
DOIs
StatePublished - 1991

Bibliographical note

Funding Information:
We thank the National Institute on Drug Abuse for grants that supported this study.

Fingerprint

Dive into the research topics of 'Cross-tolerance studies in the spinal cord of β-FNA-treated mice provides further evidence for delta opioid receptor subtypes'. Together they form a unique fingerprint.

Cite this